Tiefenbacher New Market Launch: generic launch Teriflunomide

Tiefenbacher Pharmaceuticals has successfully prepared a day one launch of the generic version of the Multiple Sclerosis (MS) medication Teriflunomide (reference brand name: Aubagio). This complex generic launch explicitly follows Tiefenbacher Group`s strategy to make high quality pharmaceuticals better affordable and better available for patients worldwide. Moreover, the low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Generally speaking, generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. Furthermore the low cost of generic medications promotes patient affordability. Also it contributes to lower per capita healthcare spending.

Teriflunomide is used to treat Multiple Sclerosis (MS), a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in Tiefenbacher Group`s own sites and will be marketed by our partners, well-known international pharmaceutical companies. Our product has already been successfully launched in the US, Canada, Mexico, and Australia – all with strict US Food and Drug Administration (FDA) standards. Further markets will follow shortly to increase the global availability of our high-quality generic medicines even more.

Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before. We will keep you updated about launches of this and other products in further international markets.